MedTrace Logo

Insulin Sensitivity During Hyperbaric Oxygen Compared to Hyperbaric Air

NCT03138746 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2020-11-04

No results posted yet for this study

Summary

In a recent series of studies performed by our group, we have shown that exposure to hyperbaric oxygen (HBO) leads to an increase in insulin sensitivity in male subjects with type-2 diabetes (T2DM) and in obese and overweight men without diabetes. The aim of this study is to investigate the relationship between pressure and oxygen in producing this effect, specifically, is this effect measurable in hyperbaric air or is some higher pressure of oxygen required?

Aims:

1. To determine whether the insulin sensitising effect of HBO is apparent in hyperbaric air at the same pressure as HBO.
2. To examine mechanisms underpinning the increase in insulin sensitivity following HBO.

Conditions

Interventions

PROCEDURE

HBO

Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a "hood" supplying high flow oxygen for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes

PROCEDURE

Hyperbaric air

Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a "hood" supplying high flow air for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes

Sponsors & Collaborators

  • Royal Adelaide Hospital

    collaborator OTHER

  • University of Adelaide

    lead OTHER

Principal Investigators

  • David C Wilkinson, FANZCA · University of Adelaide

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-13
Primary Completion
2020-01-15
Completion
2020-01-15

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03138746 on ClinicalTrials.gov